Filter Results:
(130)
Show Results For
- All HBS Web
(130)
- People (1)
- News (57)
- Research (57)
- Events (1)
- Multimedia (5)
- Faculty Publications (30)
Show Results For
- All HBS Web
(130)
- People (1)
- News (57)
- Research (57)
- Events (1)
- Multimedia (5)
- Faculty Publications (30)
Page 1 of 130
Results →
- 23 Jul 2015
- News
How Pharma Can Offer More than Pills
- 24 Jun 2016
- News
Reinventing Pharma
(photo by Claire Pearson for eyeforpharma) (photo by Claire Pearson for eyeforpharma) The newly appointed Global Head of Diversity and Inclusion at Novartis Pharma is bringing ideas from her time at HBS to drive an evolution of the... View Details
- July 1989 (Revised December 1990)
- Case
CIBA-GEIGY Pharmaceuticals: Pharma International
By: John A. Quelch
Examines the decision by Pharma International on whether to launch an antimalarial product in Nigeria and, if so, how that should be implemented. Involves commercial, ethical, and policy considerations. Rich in situation assessment data, the case refers to criticism of... View Details
Keywords: Ethics; Decision Choices and Conditions; Product Launch; Policy; Developing Countries and Economies; Pharmaceutical Industry; Nigeria
Quelch, John A. "CIBA-GEIGY Pharmaceuticals: Pharma International." Harvard Business School Case 589-108, July 1989. (Revised December 1990.)
- March 2014
- Case
Novartis' Sandoz: Between Generics and Pharma
By: Krishna Palepu and Carin-Isabel Knoop
Sandoz, which made a significant investment in bio-similars as a way to differentiate itself from its generic drug industry peers, has to negotiate with its parent company and the innovative pharma division on how best to commercialize its bio-similar portfolio. What... View Details
Keywords: Global Strategy And Leadership; Managing Within A Multi-Business Organization; Generic Pharmaceuticals; Global Strategy
Palepu, Krishna, and Carin-Isabel Knoop. "Novartis' Sandoz: Between Generics and Pharma." Harvard Business School Case 114-033, March 2014.
- March 2023 (Revised March 2024)
- Case
The Purdue Pharma Bankruptcy: Settling the Opioid Crisis
By: Kristin Mugford, Carin-Isabel Knoop and Susan Pinckney
How to get to a fair outcome for claimants in the Purdue Pharma bankruptcy given its significant role in the U.S. opioid crisis. View Details
Keywords: Regulation; Ethics; Fairness; Insolvency and Bankruptcy; Government Legislation; Courts and Trials; Laws and Statutes; Lawsuits and Litigation; Legal Liability; Crime and Corruption; Negotiation Offer; Negotiation Participants; Negotiation Style; Product Design; Product Development; Brands and Branding; Marketing Strategy; Trust; Government and Politics; Law; Negotiation; Operations; Ownership; Marketing; Social Psychology; Health Care and Treatment; Pharmaceutical Industry; United States
Mugford, Kristin, Carin-Isabel Knoop, and Susan Pinckney. "The Purdue Pharma Bankruptcy: Settling the Opioid Crisis." Harvard Business School Case 223-060, March 2023. (Revised March 2024.)
- 01 Jun 2023
- News
From Big Pharma to Startup
Hunter Goble (MBA 2022) did not enroll in Harvard Business School with dreams of becoming an entrepreneur. After earning his MBA, Goble intended to return to Eli Lilly to continue to work building brands and launching products. He envisioned himself leading a big,... View Details
Keywords: April White
- 15 Sep 2016
- News
Price of pharma innovation: Pro
- 12 May 2010
- News
Big pharma aims for reinvention
- 01 Mar 2007
- News
Pharma Suits a Farm Gal
GRAHAM: From rodeo to CEO. Amylin Pharmaceuticals CEO Ginger Graham (MBA ’86) had a good year in 2006, with Amylin stock up as much as 45 percent, with Byetta and Symlin, its two innovative diabetes drugs, performing well, and with the company added to the Nasdaq 100.... View Details
- September 2023 (Revised April 2024)
- Case
Atomwise: Strategic Opportunities in AI for Pharma
By: Satish Tadikonda
Abraham Heifets and his co-founder, Izhar Wallach, had founded Atomwise to develop i) an AI engine to transform drug discovery by creating better medicines faster, and ii) a machine learning-based discovery engine that combined the power of convolutional neural... View Details
Keywords: Business Model; Business Startups; AI and Machine Learning; Science-Based Business; Technological Innovation; Biotechnology Industry; Pharmaceutical Industry
Tadikonda, Satish. "Atomwise: Strategic Opportunities in AI for Pharma." Harvard Business School Case 824-043, September 2023. (Revised April 2024.)
- May 1998
- Background Note
Pharma Giants,The: Ready for the 21st Century?
By: Robert H. Hayes and Perry Fagan
Presents the changing competitive dynamics in the global pharmaceutical industry and possible implications for large drug companies. View Details
Hayes, Robert H., and Perry Fagan. "Pharma Giants,The: Ready for the 21st Century?" Harvard Business School Background Note 698-070, May 1998.
- 25 Jul 2023
- Research & Ideas
Could a Business Model Help Big Pharma Save Lives and Profit?
reasonable profits and reduced Hepatitis C, and rates of which are expected to fall by 86 percent between 2020 and 2030, according to Egypt’s Ministry of Health. This real-world example demonstrates how a business model can help Big View Details
- 27 Sep 2015
- News
Pharma gives drug development the Hollywood treatment
- 04 Nov 2016
- News
New war on drugs: Pharma becoming 'uninvestable'?
- 20 Mar 2015
- News
Big Pharma Needs to Get Busy in the Lab
- 27 Sep 2016
- News
Mylan CEO's testimony was a huge blow to the entire pharma industry
- April 2011 (Revised April 2015)
- Case
Cipla 2011
By: Rohit Deshpande, Sandra J. Sucher and Laura Winig
Dr. Yusuf Hamied, head of the Indian pharma and generics manufacturing company Cipla, is weighing options for how to continue to support the global fight against HIV/AIDS while positioning his company for growth in a changing regulatory landscape. View Details
Keywords: Leadership; Leading Change; Leadership Style; Management Teams; Governance Compliance; Corporate Strategy; Pharmaceutical Industry
Deshpande, Rohit, Sandra J. Sucher, and Laura Winig. "Cipla 2011." Harvard Business School Case 511-050, April 2011. (Revised April 2015.)
- June 1998
- Supplement
MBA Integrative Exercise: General Management, April 1998
By: Carin-Isabel Knoop
Drummond Paris, Regional Pharma Head, Asia/Pacific Novartis AG, discusses the company situation in Indonesia: joint ventures, budget, keeping track, and the prognosis for the future. View Details
Keywords: Business or Company Management; Joint Ventures; Forecasting and Prediction; Pharmaceutical Industry; Indonesia
Knoop, Carin-Isabel. "MBA Integrative Exercise: General Management, April 1998." Harvard Business School Video Supplement 898-503, June 1998.